Use of SGLT-2 Inhibitors and Obesity Drugs

Project Title Use of SGLT-2 Inhibitors and Obesity Drugs
Date Posted
Friday, November 8, 2019
Project ID
cder_str_wp129-132
Status
Complete
Deliverables
Related Links
Description

In these reports, we present incident and prevalent use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and obesity drugs dispensed in the Sentinel Distributed Database (SDD). This request contains 4 reports:

  • Report 1 (cder_str_wp129): This report presents total and incident counts of dispensings of nine generic obesity drugs among enrolled members in the SDD from 2008 to 2017. This request was distributed to Data Partners on May 15, 2019.
  • Report 2 (cder_str_wp130): This report presents total and prevalent counts of dispensings of nine generic obesity drugs among enrolled members in the SDD from 2008 to 2017. This request was distributed to Data Partners on May 15, 2019.
  • Report 3 (cder_str_wp131): This report presents total and incident counts of dispensings of eleven generic SGLT-2 inhibitor drugs among enrolled members in the SDD from 2008 to 2017. This request was distributed to Data Partners on May 17, 2019.
  • Report 4 (cder_str_wp132): This report presents total and prevalent counts of dispensings of eleven generic SGLT-2 inhibitor drugs among enrolled members in the SDD from 2008 to 2017. This request was distributed to Data Partners on May 17, 2019.
Medical Product
benzphetamine HCl
canagliflozin
canagliflozin/metformin HCl
dapagliflozin propanediol
dapagliflozin/metformin HCl
dapagliflozin/saxagliptin HCl
diethylproprion HCl
empagliflozin
empagliflozin/linagliptin
empagliflozin/metformin HCl
ertugliflozin pidolate
ertugliflozin/metformin
ertugliflozin/sitagliptin
liraglutide
lorcaserin HCl
naltrexone HCl/buproprion HCl
orlistat
phendimetrazine tartrate
phentermine HCl
phentermine/topiramate
Population / Cohort
All individuals
Time Period
January 1, 2008 - December 31, 2017
Study Type
Summary Table
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER